EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy

In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer. Dr. Wakelee explains that MET amplification and related alterations are among the more common mechanisms of resistance following EGFR tyrosine kinase inhibitor therapy, making molecular reassessment critical at progression. She highlights how recent studies evaluating MET-directed strategies are helping define targeted treatment approaches for these patients. The discussion emphasizes the importance of identifying actionable resistance pathways to guide therapy selection rather than relying on empiric treatment. Dr. Wakelee also notes that while these strategies are promising, their application depends on accurate detection of MET alterations and patient-specific clinical factors. Overall, this segment underscores the growing role of biomarker-driven sequencing and the importance of integrating emerging clinical evidence into second-line treatment decisions in EGFR-mutated NSCLC.